Bioequivalence and Ethics Committee Inspection
Bioequivalence (BE) studies are required for all generic medicines in the form of:
- immediate release, oral solid dosage [effective 1 January 2012]
- modified release (extended, prolonged, sustained release, etc.) [effective 12 June 2013]
- effervescent, dispersible, orodispersible, sublingual, buccal and chewable [effective 1 January 2018]
Recent Updates / Announcements
Application Forms for Clinical Trial |
Prosedur dan Kriteria Pelanjutan Tempoh Sah Pusat Kajian Bioekuivalens (BE) dan Jawatankuasa Etika yang berdaftar dengan Pihak Berkuasa Kawalan Dadah (PBKD) |
Penerbitan Garis Panduan Malaysian Guideline For Bioequivalence Inspection Edisi Kedua |
NOTIS MAKLUMAN URUSAN PEMBAYARAN BANK DRAF ATAU KIRIMAN WANG BAGI PERMOHONAN PEMERIKSAAN PUSAT KAJIAN BE |
[CLOSED] Public Consultation: Malaysian Guideline for Bioequivalence Inspection 2nd Edition |
- BEDN - Related to inspection application for local BE
- BELN - Related to inspection application for foreign BE
- BEDE - Related to application for evaluation to determine the need for BE study inspection
- ECI - Related to registration and inspection application for ethics committee
- ECU - Any updates related to ethics committee registered with Drug Controlled Authority (DCA) such as updated list of membership or annual report
- QUERY - Any general enquiries
As example: BEDN – Inspection application for BE centre ABC.